Abstracts tagged "Lupus nephritis"

Abstract Number: 0047 • ACR Convergence 2025
Monocyte Transcriptomic Signatures Uncover Potential Pathogenic Mechanisms of the APOL1 High Risk Genotype (HRG)
Vishnuprabu Pandian¹, Adebola Agboola¹, Sivasubramanian ramani², Christele Felix³, Andrra Nimoni³, Jasmin Divers⁴, Timothy Niewold⁵ and Ashira Blazer², ¹University of Maryland, Baltimore, Baltimore, Maryland, ²University of Maryland Baltimore, Baltimore, Maryland, ³Hospital for Special Surgery, New York, NY, ⁴NYU Grossman Long Island School of Medicine, New York, New York, ⁵Hospital for Special Surgery, New York, New York
Background/Purpose: Compared to the low-risk genotype (LRG) the APOL1 high-risk genotype (HRG) confers an increased risk of end stage kidney disease among individuals with systemic…
Abstract Number: 2467 • ACR Convergence 2025
Complete Renal Responses and Safety for Belimumab Versus Placebo in a Post Hoc Mycophenolate Mofetil Subgroup with Active Proliferative Lupus Nephritis
Richard Furie¹, Hans-Joachim Anders², George Bertsias³, Ana Delgado⁴, Roger A. Levy⁵, Paula Curtis⁶, Ciara O'Shea⁷, Ryan Tomlinson⁸ and Brad Rovin⁹, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Hospital of LMU Munich, Department of Medicine IV, Munich, Germany, ³Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, ⁴GSK, Immunology Medical Affairs, London, United Kingdom, ⁵GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁶GSK, Biostatistics, London, United Kingdom, ⁷Global Medical Affairs, GSK, Dublin, Ireland, ⁸GSK, Development – R&D, Collegeville, PA, ⁹The Ohio State University, Columbus, OH
Background/Purpose: Belimumab, a human IgG1λ monoclonal antibody that selectively binds B-lymphocyte stimulator, was first approved in 2011. It is the only biologic approved for LN…
Abstract Number: 2399 • ACR Convergence 2025
Identification of an LN endotype linked to intestinal expansion of Pathogenic Strains of a Pathobiont Bacterium that induces Systemic Thrombo-inflammatory Pathways directly measurable in Urine
Gregg Silverman¹, Abhimanyu Amarnani², Zakia Azad² and Brad Rovin³, ¹NYU Grossman School of Medicine, New York, NY, ²New York University Grossman School of Medicine, New York, NY, ³The Ohio State University, Columbus, OH
Background/Purpose: During disease, ~50% of SLE patients develop lupus nephritis (LN), one of the most serious complication. Despite the best therapy, within 15 years, ~20%…
Abstract Number: 1721 • ACR Convergence 2025
Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study
Mario Bautista-Vargas¹, Erika Navarro-Mendoza¹, Jaime Flores-Gouyonnet¹, Ali Ardekani¹, Maria Cuellar-Gutierrez¹, Gabriel Figueroa-Parra², Mariana Gonzalez-Treviño³, Jose Antonio Meade-Aguilar⁴, Alain Sanchez-Rodriguez⁵, Andrew C. Hanson¹, Cassondra Hulshizer⁶, Cynthia Crowson⁷ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Boston University/Boston Medical Center, Boston, MA, ⁵ABC Medical Center, Ciudad de México, Federal District, Mexico, ⁶Mayo Clinic, Rochester, ⁷Mayo Clinic, Stewartvillle, MN
Background/Purpose: Five-year survival in SLE has plateaued since the 1990s. Most epidemiologic studies pool all SLE phenotypes; It is possible that the excess mortality observed…
Abstract Number: 1480 • ACR Convergence 2025
Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
CHEN-YU LEE¹, Rufei Lu², Carla Guthridge², Wade DeJager³, Jennifer Barnas⁴, Jennifer Anolik⁵, H Michael Belmont⁶, Judith James², Jill Buyon⁷, Brad Rovin⁸, Michelle Petri⁹, Joel Guthridge² and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴University of Rochester, Rochester, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶NYU School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸The Ohio State University, Columbus, OH, ⁹Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Early treatment is critical to prevent irreversible kidney damage in lupus nephritis (LN). Current guidelines recommend kidney biopsy when the urine protein-to-creatinine ratio (UPCR)…
Abstract Number: 0667 • ACR Convergence 2025
Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN
Sawyer May¹, Lynn Price¹ and Ryan Rex², ¹Spherix Global Insights, Exton, PA, ²Spherix Global Insights, Chester Springs, PA
Background/Purpose: In May 2025, ACR released updated recommendations for the management of LN2. Notably, since the previous guidelines update in 2012, the FDA has approved…
Abstract Number: 0613 • ACR Convergence 2025
A Baseline Kidney Biopsy Is Not Always Feasible in Incident Lupus Nephritis: Insights From an Inception Cohort
Fadi Kharouf¹, Pankti Mehta², Qixuan Li³, Dafna D. Gladman⁴, Zahi Touma⁵ and Laura Whitall Garcia⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada
Background/Purpose: Baseline kidney biopsy is the gold standard for diagnosing incident lupus nephritis (LN). However, in certain cases, obtaining a biopsy may not be feasible…
Abstract Number: 0002 • ACR Convergence 2025
KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
Brian Kim, Christine Lowe, Francisco Flores, Jeremy Margaitis, Alessandro Calo, Stacey Valny, Anna Konecny, Eva Jaghatspanyan, Sean Yoder, Kenneth Ertel, Simone Filosto, Jodi Murakami and David Barrett, Kite, a Gilead Company, Santa Monica, CA
Background/Purpose: B-cell dysregulation is a key factor in the development and progression of autoimmune diseases, and B-cell inhibition has been a cornerstone of treatment for…
Abstract Number: 2466 • ACR Convergence 2025
Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis
Richard Furie¹, Neel Anand², Shraddha Desai³, Eric Lowe⁴, Tony Muchamuel³, Kiruthi Palaniswamy², Rachel Peterson², Kathryn Ray², Zung To², Jennifer Whang² and Richard Leff⁵, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Kezar Life Sciences, Inc, South San Francisco, CA, ³Kezar Life Sciences, Inc, South San Francisco, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Richard L Leff MD LLC, Chadds Ford, PA
Background/Purpose: Zetomipzomib (zeto), a selective immunoproteasome inhibitor, has previously shown anti-inflammatory activity in patients (pts) with SLE and LN in the open-label MISSION study. The…
Abstract Number: 2392 • ACR Convergence 2025
Does Obesity Influence Disease Activity and Biomarkers in Systemic Lupus Erythematosus Patients?: A Retrospective Study
Daniyal Nadeem¹, Anusheh Ali², Shravya Balmuri², Megan Mattison³, Upasana Agrawal⁴, Alexandra Zamora-Smith⁵, Karan Sachdeva⁶, Teresa leeth¹, Robert Quinet⁷, William Davis⁸, Jerald Zakem⁹, Chandana Keshavamurthy¹⁰, Xin Zhang¹¹, Sarwat Umer¹² and Samina Hayat¹³, ¹Louisiana State University Health Science, Shreveport, LA, ²Louisiana State University, Shreveport, LA, ³Louisiana State University- Shreveport, Shreveport, LA, ⁴Louisiana State University Health Sciences, Shreveport, Shreveport, LA, ⁵LSU Health Science Center in Shreveport, Shreveport, LA, ⁶Louisiana state university health shreveport, shreveport, ⁷Department of Rheumatology, Ochsner Health, New Orleans, LA, ⁸Ochsner Health System, New Orleans, LA, ⁹Ochsner Health Systems, Metairie, LA, ¹⁰banner university medical center, phoenix, AZ, ¹¹Ochsner Medical Center, New Orleans, LA, ¹²LSUHSC Shreveport, Shreveport, LA, ¹³Louisiana state university Shreveport, Shreveport, LA
Background/Purpose: Obesity, a prevalent condition, is known to exacerbate inflammation and could potentially influence the progression and severity of autoimmune diseases like Systemic lupus erythematosus…
Abstract Number: 1547 • ACR Convergence 2025
Anifrolumab In Systemic Lupus Erythematosus With Renal Involvement: National Multicenter Registry In Clinical Practice
Vanesa Calvo-Río¹, Carmen Secada-Gómez¹, Blanca Garcia-Magallon², Deseada Palma-Sanchez³, Andrea García-Valle⁴, Irati Urionaguena Onaindia⁵, Adrián Mayo-Juanatey⁶, Paúl Hernández Velasco⁷, GUILLERMO GONZALEZ ARRIBAS⁸, Ana Pareja-Martínez⁹, Montserrat Corteguera¹⁰, Guillen Sada Urmeneta¹¹, Paz Collado Ramos¹², Jose Luis Tandaipan¹³, Juan Roberto Miguelez Sanchez¹⁴ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Rheumatology. Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, ⁴Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ⁵Rheumatology.Hospital Galdakao, Vizcaya, Pais Vasco, Spain, ⁶Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ⁷Nephrology, Hospital Universitario ¹² de Octubre, Madrid. Spain, Madrid, Madrid, Spain, ⁸Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ⁹Rheumatology. Hospital Universitario Infanta Leonor, Madrid, Madrid, Spain, ¹⁰Rheumatology. Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, ¹¹Rheumatology. Hospital Reina Sofía, Tudela, Navarra, Spain, ¹²Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain,, MADRID, Madrid, Spain, ¹³Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁴Department of Rheumatology, Hospital Universtiario de Móstoles, Madrid, Spain, Madrid, Madrid, Spain
Background/Purpose: Lupus Nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), occurring in up to 50% of patients. Currently, Anifrolumab (ANI) is approved…
Abstract Number: 1476 • ACR Convergence 2025
Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus: A Meta-Analysis of Prevalence and Clinical Correlates
Bana Shawareb¹, Muhannad Haddadin¹, Ansaam Daoud² and Omer Pamuk³, ¹Cleveland Clinic Akron General, Akron, OH, ²Case Western Reserve University/University Hospitals, Cleveland, OH, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by widespread immune dysregulation and multi-organ involvement. Autoimmune hemolytic anemia (AIHA), marked by antibody-mediated…
Abstract Number: 0665 • ACR Convergence 2025
Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
Richard Furie¹, Teresa Baczkowska², Amit Saxena³, Imran Hassan⁴, Bongin Yoo⁵, Ben Lanza⁶, Himanshi Sehgal⁷, Frederic Boissard⁷, Jay Garg⁵, Thomas Schindler⁷, Elsa Martins⁷, William Pendergraft⁵ and Brad Rovin⁸, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, ³Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁴Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸The Ohio State University, Columbus, OH
Background/Purpose: The REGENCY (NCT04221477) trial demonstrated superior efficacy of obinutuzumab and standard therapy (OBI+ST) over placebo and ST (PBO+ST) in patients (pts) with active lupus…
Abstract Number: 0612 • ACR Convergence 2025
Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
Fadi Kharouf¹, JuanPablo Diaz Martinez², Pankti Mehta³, Dafna D. Gladman⁴, Laura Whitall Garcia⁵ and Zahi Touma⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarials, particularly hydroxychloroquine, are a cornerstone of systemic lupus erythematosus (SLE) management, with well-established benefits including reduced disease activity, prevention of flares, and mitigation…
Abstract Number: 2460 • ACR Convergence 2025
Comparative Efficacy of Belimumab, Anifrolumab, and Rituximab in SLE: A Retrospective Analysis of Serological and Clinical Outcomes
Pablo Martínez Calabuig¹, Jorge Juan Fragío Gil², Roxana González Mazario³, Laura Salvador Maicas⁴, Mireia Sanmartin Martínez⁴, Iván Jesús Lorente Betanzos⁴, Amalia Rueda Cid⁴, Juan José Lerma Garrido⁴, Isabel Martínez Cordellat⁴, Isabel Balaguer Trull⁴, Berta Gómez Correas⁴ and Cristina Campos Fernández³, ¹Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ²Hospital General Universitario, Valencia, Spain, ³Hospital General de Valencia, Valencia, Spain, ⁴Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystem involvement and fluctuating activity. Biologic therapies such as Belimumab, Anifrolumab, and Rituximab offer…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].